Intestinal Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INT253 MIFTS: 44	Intestinal Benign Neoplasm Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Intestinal Benign Neoplasm

MalaCards integrated aliases for Intestinal Benign Neoplasm:

Name: Intestinal Benign Neoplasm ¹² ¹⁵

Intestinal Neoplasms ⁴³ ⁷¹

Neoplasm of Intestinal Tract ¹²

Intestinal Tumors ¹²

Intestine Growth ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4610

MeSH ⁴³ D007414

NCIt ⁴⁹ C3141

UMLS ⁷¹ C0021841

Sources

Summaries for Intestinal Benign Neoplasm

Disease Ontology : ¹² A gastrointestinal system benign neoplasm that is located in the intestine.

MalaCards based summary : Intestinal Benign Neoplasm, also known as intestinal neoplasms, is related to colorectal adenoma and gastric cancer, and has symptoms including constipation and diarrhea. An important gene associated with Intestinal Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are DNA Damage Response and Proteoglycans in cancer. The drugs Glucagon and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include intestine, colon and t cells.

Sources

Related Diseases for Intestinal Benign Neoplasm

Diseases related to Intestinal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)

#	Related Disease	Score	Top Affiliating Genes
1	colorectal adenoma	32.4	TP53 MUTYH MIR21 MIR17 MIR15A KRAS
2	gastric cancer	32.3	TP53 MUTYH MIR31 MIR21 MIR20A MIR192
3	colonic benign neoplasm	32.0	TP53 MIR532 MIR20A MIR18A MIR15A MIR143
4	adenoma	31.6	TP53 MUTYH KRAS APC
5	familial adenomatous polyposis	31.4	TP53 MUTYH KRAS HRAS APC
6	small intestine cancer	31.1	TP53 MUTYH KRAS HRAS
7	neurofibromatosis, type iv, of riccardi	30.5	TP53 KRAS HRAS
8	duodenum cancer	30.5	MUTYH KRAS HRAS
9	colon adenocarcinoma	30.4	TP53 MIR21 KRAS APC
10	peptic ulcer disease	30.2	TP53 HRAS H2AC18
11	pancreatitis	30.2	TP53 MIR21 KRAS HRAS
12	colorectal cancer	30.0	TP53 MUTYH MIR31 MIR21 MIR20A MIR192
13	lynch syndrome	29.9	TP53 MUTYH MIR532 MIR17 KRAS HRAS
14	myeloma, multiple	29.8	TP53 MIR21 MIR17 MIR15A MIR142 KRAS
15	rectum cancer	29.7	MUTYH MIR31 MIR21 MIR20A MIR17 MIR143
16	pancreatic cancer	29.6	TP53 MIR21 MIR20A MIR17 MIR15A MIR143
17	esophageal cancer	29.6	TP53 MIR31 MIR21 MIR192 MIR143 MIR142
18	gastrointestinal system cancer	29.6	MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A
19	intestinal disease	29.4	TP53 MIR532 MIR31 MIR21 MIR20A MIR192
20	gastrointestinal system disease	29.4	MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A
21	small intestine benign neoplasm	12.4
22	large intestine adenoma	11.2
23	cecal benign neoplasm	11.2
24	small intestine leiomyoma	11.2
25	large bowel leiomyoma	11.2
26	large intestine lipoma	11.2
27	rare tumor of intestine	11.1
28	omphalocele	11.0
29	feingold syndrome 1	10.7	MIR20A MIR18A MIR17
30	signet ring basal cell carcinoma	10.7	KRAS HRAS
31	ampulla of vater neoplasm	10.7	KRAS HRAS APC
32	periampullary adenoma	10.7	KRAS HRAS APC
33	thyroid gland anaplastic carcinoma	10.7	TP53 MIR18A MIR17
34	attenuated familial adenomatous polyposis	10.7	MUTYH APC
35	trachea carcinoma in situ	10.7	KRAS HRAS
36	hepatic flexure cancer	10.7	KRAS APOLD1
37	duodenal benign neoplasm	10.7	HRAS APC
38	polyposis syndrome, hereditary mixed, 1	10.7	MUTYH APC
39	nasal cavity adenocarcinoma	10.7	KRAS HRAS
40	esophagus adenocarcinoma	10.7	TP53 MIR21 MIR143
41	bronchiolo-alveolar adenocarcinoma	10.7	MIR31 MIR17 KRAS
42	ascending colon cancer	10.7	KRAS HRAS APOLD1
43	anal carcinoma in situ	10.7	TP53 APOLD1
44	lichen disease	10.7	TP53 MIR31 CCR6
45	extrinsic cardiomyopathy	10.7	MIR21 H2AC18 CCR6
46	malignant anus melanoma	10.7	HRAS APOLD1
47	connective tissue benign neoplasm	10.7	TP53 MUTYH APC
48	herpangina	10.6	TP53 H2AC18 CCR6
49	parasitic helminthiasis infectious disease	10.6	MIR21 H2AC18 CCR6
50	familial colorectal cancer	10.6	TP53 MUTYH APC

Graphical network of the top 20 diseases related to Intestinal Benign Neoplasm:

Sources

Symptoms & Phenotypes for Intestinal Benign Neoplasm

UMLS symptoms related to Intestinal Benign Neoplasm:

constipation, diarrhea

Sources

Drugs & Therapeutics for Intestinal Benign Neoplasm

Drugs for Intestinal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Glucagon

Approved

Phase 4

16941-32-5

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Bisacodyl

Approved

Phase 4

603-50-9

Glucagon-Like Peptide 1

Phase 4

Fibrinolytic Agents

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Antipyretics

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Cathartics

Phase 4

Laxatives

Phase 4

glutamine

Phase 4

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1

2764

Orange

Approved

Phase 3

Clavulanate

Approved, Vet_approved

Phase 3

58001-44-8

5280980

Amoxicillin

Approved, Vet_approved

Phase 3

26787-78-0

33613

Simvastatin

Approved

Phase 3

79902-63-9

54454

Celecoxib

Approved, Investigational

Phase 2, Phase 3

169590-42-5

2662

Ursodeoxycholic acid

Approved, Investigational

Phase 2, Phase 3

128-13-2

31401

Ondansetron

Approved

Phase 3

99614-02-5

4595

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Guaifenesin

Approved, Investigational, Vet_approved

Phase 3

93-14-1

3516

Dextromethorphan

Approved

Phase 3

125-71-3

5360696 5362449

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030 46835353

Everolimus

Approved

Phase 3

159351-69-6

6442177 70789204

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

Calcium

Approved, Nutraceutical

Phase 3

7440-70-2

271

Antitubercular Agents

Phase 3

Amoxicillin-Potassium Clavulanate Combination

Phase 3

beta-Lactamase Inhibitors

Phase 3

Gastrointestinal Agents

Phase 3

Anti-Infective Agents

Phase 3

Anti-Bacterial Agents

Phase 3

Topoisomerase Inhibitors

Phase 3

Hypolipidemic Agents

Phase 3

Anticholesteremic Agents

Phase 3

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 3

Calcium, Dietary

Phase 3

Lipid Regulating Agents

Phase 3

Analgesics

Phase 3

Cholagogues and Choleretics

Phase 2, Phase 3

Cyclooxygenase 2 Inhibitors

Phase 2, Phase 3

Hematinics

Phase 3

Epoetin alfa

Phase 3

113427-24-0

Dermatologic Agents

Phase 3

Antiemetics

Phase 3

Neurotransmitter Agents

Phase 3

Autonomic Agents

Phase 3

Interventional clinical trials:

(show top 50) (show all 170)

#	Name	Status	NCT ID	Phase	Drugs
1	Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2	Unknown status	NCT00473733	Phase 4
2	The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial	Unknown status	NCT01549418	Phase 4	Aspirin (ASA);Placebo
3	Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial.	Completed	NCT01887158	Phase 4	Polyethylene glycol;Bisacodyl
4	The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study	Completed	NCT01552291	Phase 4	Placebo
5	A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer	Unknown status	NCT03303495	Phase 3	CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
6	Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study.	Unknown status	NCT02608203	Phase 2, Phase 3	[68Ga]-DOTANOC PET/CT
7	A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE]	Unknown status	NCT00445497	Phase 3	amoxicillin-clavulanate potassium;ciprofloxacin
8	Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer	Completed	NCT03350490	Phase 2, Phase 3	Life information rehabilitation therapy
9	Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery	Completed	NCT00994903	Phase 3	Simvastatin;Placebo
10	Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)	Completed	NCT00808743	Phase 2, Phase 3	Celecoxib;Ursodeoxycholic acid;Placebo
11	A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy	Completed	NCT00003600	Phase 3
12	A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer	Completed	NCT01996306	Phase 3	CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
13	Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer	Completed	NCT01269567	Phase 3
14	Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer	Completed	NCT00006348	Phase 3	ondansetron
15	A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors	Completed	NCT00005590	Phase 3	levofloxacin
16	A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients	Completed	NCT00003687	Phase 3	dextromethorphan hydrobromide;morphine sulfate
17	A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients	Recruiting	NCT03464305	Phase 3	acetylsalicylic acid;Placebo
18	Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)	Recruiting	NCT03375320	Phase 3	Cabozantinib S-malate
19	A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).	Active, not recruiting	NCT02753127	Phase 3	Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
20	Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis	Withdrawn	NCT00026468	Phase 2, Phase 3	exisulind
21	Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery	Unknown status	NCT02202928	Phase 2	Chemotherapy
22	Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma	Unknown status	NCT00410462	Phase 2	brostallicin;doxorubicin hydrochloride
23	A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas	Unknown status	NCT00669812	Phase 2	carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
24	A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.	Completed	NCT01941966	Phase 2	Capecitabine;Mitomycins
25	An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer	Completed	NCT01397305	Phase 1, Phase 2	[6R] 5,10-methylenetetrahydrofolate;Pemetrexed
26	A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin® (60 or 200mg/m2) Compared to Levoleucovorin (60 or 200mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer	Completed	NCT01681472	Phase 1, Phase 2	6R-MTHF 200 mg/m2;Levoleucovorin 200 mg/m2;6R-MTHF 60 mg/m2;Levoleucovorin 60 mg/m2
27	Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas	Completed	NCT00005874	Phase 2	rubitecan
28	Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult	Completed	NCT00003939	Phase 2	trabectedin
29	Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer	Completed	NCT01016639	Phase 1, Phase 2
30	Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies	Completed	NCT00005049	Phase 2	carboplatin;cisplatin;floxuridine
31	A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy	Completed	NCT00004911	Phase 1, Phase 2
32	A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy	Completed	NCT00004910	Phase 1, Phase 2
33	Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study	Completed	NCT00004895	Phase 2	octreotide acetate
34	A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma	Completed	NCT00004066	Phase 2	docetaxel;gemcitabine hydrochloride
35	A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma	Completed	NCT00454363	Phase 2	Pazopanib Hydrochloride
36	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
37	Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors	Completed	NCT01177007	Phase 2
38	A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma	Completed	NCT00433550	Phase 2	capecitabine;irinotecan hydrochloride;oxaliplatin
39	Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer	Completed	NCT00019474	Phase 2	fluorouracil;hydroxyurea
40	Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma	Completed	NCT00006357	Phase 1, Phase 2	imatinib mesylate
41	Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma	Completed	NCT00079261	Phase 2	CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
42	Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma	Completed	NCT00006039	Phase 2
43	A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas	Completed	NCT00474994	Phase 2	sunitinib malate
44	MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood	Completed	NCT00025441	Phase 2	carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
45	Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia	Completed	NCT00006379	Phase 2	cyclophosphamide;fludarabine phosphate
46	Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen	Completed	NCT00005804	Phase 2	cyclophosphamide
47	A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation	Completed	NCT00589563	Phase 2	cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
48	A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3	Recruiting	NCT03457844	Phase 2	Anlotinib
49	Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors	Recruiting	NCT02185443	Phase 2
50	Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors	Recruiting	NCT03043664	Phase 1, Phase 2	Somatuline Depot;Keytruda

Search NIH Clinical Center for Intestinal Benign Neoplasm

Cochrane evidence based reviews: intestinal neoplasms

Sources

Genetic Tests for Intestinal Benign Neoplasm

Sources

Anatomical Context for Intestinal Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Benign Neoplasm:

¹⁹

Intestine

MalaCards organs/tissues related to Intestinal Benign Neoplasm:

⁴⁰

Colon, T Cells, Small Intestine, Testes, Lung, Thyroid, Breast

Sources

Publications for Intestinal Benign Neoplasm

Articles related to Intestinal Benign Neoplasm:

(show top 50) (show all 145)

#	Title	Authors	PMID	Year
1	Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. ⁵⁴ ⁶¹	Munoz NM...Grady WM	17047044	2006
2	Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. ⁵⁴ ⁶¹	Greiner JW...Schlom J	12460911	2002
3	Large esophageal schwannoma: En-bloc resection with primary closure by esophagoplasty. ⁶¹	Degheili JA...Hallal AH	31351369	2019
4	Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. ⁶¹	Berger EP...Musser ML	30307656	2018
5	Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation. ⁶¹	van Lidth de Jeude JF...Heijmans J	30232220	2018
6	The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia. ⁶¹	Orhan A...Kissow H	29741675	2018
7	Transmission of a common intestinal neoplasm in zebrafish by cohabitation. ⁶¹	Burns AR...Kent ML	29023774	2018
8	Primary neoplasms of the small bowel at CT: a pictorial essay for the clinician. ⁶¹	Minordi LM...Manfredi R	29461587	2018
9	Hypothesis: Induction of biomarkers for detection of colonic neoplasms. ⁶¹	Bordonaro M...Lazarova D	29290782	2018
10	A Peutz-Jeghers syndrome family associated with sinonasal adenocarcinoma: 28 years follow up report. ⁶¹	Chiang JM...Chen TC	28391433	2017
11	Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. ⁶¹	Sharma P...Masoud A	28523628	2017
12	Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to tumor propagation via clonal expansion. ⁶¹	Yanai H...Ueno H	28176811	2017
13	Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms. ⁶¹	Morris SM...Grady WM	27790711	2017
14	Altered T-Cell Balance in Lymphoid Organs of a Mouse Model of Colorectal Cancer. ⁶¹	Tanner SM...Lorenz RG	27798287	2016
15	[Application of magnetic resonance enterography for diagnosis of small intestinal diseases in children]. ⁶¹	Lou J...Chen J	26791925	2016
16	Immunohistochemical characterization of intestinal neoplasia in zebrafish Danio rerio indicates epithelial origin. ⁶¹	Paquette CE...Lohr CV	26503773	2015
17	One stage curative resection of double intestinal neuroendocrine tumors with thirty-two bilobar liver metastases. A case report. ⁶¹	Mirarchi M...Cola B	26344670	2015
18	NON-CELIAC SPRUE: A CASE OF OLMESARTAN-INDUCED ENTEROPATHY. ⁶¹	Penn W...Bruce Z	27159470	2015
19	Foot infection by Clostridium sordellii: case report and review of 15 cases in France. ⁶¹	Bouvet P...Popoff MR	25609723	2015
20	Recent advances in intestinal lymphomas. ⁶¹	Foukas PG...de Leval L	25639480	2015
21	The hierarchical model of stem cell genesis explains the man mouse paradox, Peto's paradox, the red cell paradox and Wright's enigma. ⁶¹	Morris JA	25459141	2014
22	Polypoid arteriovenous malformation presenting with jejunojejunal intussusceptions in an adult. ⁶¹	Lim DH...Park YS	25505727	2014
23	A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. ⁶¹	Thompson CM...Harris MA	23943231	2014
24	Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. ⁶¹	Bongers G...Lira SA	24590763	2014
25	Pediatric ileoileal intussusception with a lipoma lead point: a case report. ⁶¹	Asaumi Y...Hashizume Y	24760240	2014
26	Pediatric and adult celiac disease: similarities and differences. ⁶¹	Poddar U	23715643	2013
27	Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. ⁶¹	Ivancic MM...Sussman MR	23924158	2013
28	Genetic control of intestinal stem cell specification and development: a comparative view. ⁶¹	Takashima S...Hartenstein V	22529012	2012
29	Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms. ⁶¹	Amos-Landgraf JM...Dove WF	22308460	2012
30	Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. ⁶¹	Hernandez V...Clofent J	24714149	2012
31	Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. ⁶¹	Yang SJ...Shieh MJ	21163518	2011
32	C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms. ⁶¹	Hata K...Hirose Y	22174655	2011
33	Diffuse infantile hemangiomatosis of the ileum presenting with multiple perforations: a case report and review of the literature. ⁶¹	Rao AB...Mirkin DL	20850639	2010
34	[Clinicopathological features of small intestinal tumors]. ⁶¹	Yao T	20716865	2010
35	Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. ⁶¹	Zhang L...Wu X	20348907	2010
36	Surgical treatment of small bowel neoplasms. ⁶¹	Coco C...Verbo A	20496543	2010
37	Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. ⁶¹	Borinstein SC...Grady WM	19777566	2010
38	PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. ⁶¹	Pysz MA...Black JD	19232344	2009
39	TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. ⁶¹	Trobridge P...Grady WM	19208363	2009
40	The epidemiology and pathogenesis of neoplasia in the small intestine. ⁶¹	Schottenfeld D...Vigneau FD	19064190	2009
41	N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies. ⁶¹	Morton D...Ball DJ	18827072	2008
42	Primary melanoma of small intestine masquerading as gastrointestinal stromal tumor: a case report and literature review. ⁶¹	Gabali AM...Ganesan S	18453296	2008
43	Colorectal cancer risk in Crohn's disease. ⁶¹	Freeman HJ	18350616	2008
44	[Clinical analysis of primary small intestinal neoplasms in 305 cases]. ⁶¹	Yang WL...Wang YJ	18396694	2007
45	Carcinoid tumors are 15 times more common in patients with Crohn's disease. ⁶¹	West NE...Schwartz DA	17538985	2007
46	[A rare cause of bleeding intestinal intussusception in adult: jejunal lipoma]. ⁶¹	Yigitler C...Oner K	17978901	2007
47	Effect of dietary resistant starch and protein on colonic fermentation and intestinal tumourigenesis in rats. ⁶¹	Le Leu RK...Young GP	17166881	2007
48	Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. ⁶¹	Katsanos KH...EC-IBD Study Group	17598963	2007
49	Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. ⁶¹	Powell DW...Mifflin RC	15961883	2005
50	Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer. ⁶¹	Di Marzio L...Cifone MG	15824156	2005

Sources

Genes for Intestinal Benign Neoplasm

Genes related to Intestinal Benign Neoplasm (0 elite genes):

(show top 50) (show all 52)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	14.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	12460911 17047044
2	MIR21	MicroRNA 21	RNA Gene	10.31	DISEASES inferred ¹⁵ ¹⁵
3	MIR17	MicroRNA 17	RNA Gene	10.12	DISEASES inferred ¹⁵ ¹⁵
4	MIR18A	MicroRNA 18a	RNA Gene	10.07	DISEASES inferred ¹⁵ ¹⁵
5	MIR143	MicroRNA 143	RNA Gene	9.97	DISEASES inferred ¹⁵ ¹⁵
6	MIR532	MicroRNA 532	RNA Gene	9.45	DISEASES inferred ¹⁵ ¹⁵
7	MIR31	MicroRNA 31	RNA Gene	9.3	DISEASES inferred ¹⁵ ¹⁵
8	MIR20A	MicroRNA 20a	RNA Gene	9.07	DISEASES inferred ¹⁵ ¹⁵
9	MIR139	MicroRNA 139	RNA Gene	8.97	DISEASES inferred ¹⁵ ¹⁵
10	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	8.6	DISEASES inferred ¹⁵ ¹⁵
11	H2AC18	H2A Clustered Histone 18	Protein Coding	8.59	DISEASES inferred ¹⁵ ¹⁵
12	MIR15A	MicroRNA 15a	RNA Gene	8.58	DISEASES inferred ¹⁵ ¹⁵
13	MIR192	MicroRNA 192	RNA Gene	8.44	DISEASES inferred ¹⁵ ¹⁵
14	APOLD1	Apolipoprotein L Domain Containing 1	Protein Coding	8.21	DISEASES inferred ¹⁵
15	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	8.12	DISEASES inferred ¹⁵
16	MIR142	MicroRNA 142	RNA Gene	8.1	DISEASES inferred ¹⁵ ¹⁵
17	MIR124-1	MicroRNA 124-1	RNA Gene	8.08	DISEASES inferred ¹⁵ ¹⁵
18	MUTYH	MutY DNA Glycosylase	Protein Coding	8.05	DISEASES inferred ¹⁵
19	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	7.98	DISEASES inferred ¹⁵
20	TP53	Tumor Protein P53	Protein Coding	7.83	DISEASES inferred ¹⁵
21	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	7.76	DISEASES inferred ¹⁵
22	CTNNB1	Catenin Beta 1	Protein Coding	7.75	DISEASES inferred ¹⁵
23	MIR199A1	MicroRNA 199a-1	RNA Gene	7.7	DISEASES inferred ¹⁵ ¹⁵
24	MIR10A	MicroRNA 10a	RNA Gene	7.68	DISEASES inferred ¹⁵ ¹⁵
25	MLH1	MutL Homolog 1	Protein Coding	7.65	DISEASES inferred ¹⁵
26	LGR5	Leucine Rich Repeat Containing G Protein-Coupled Receptor 5	Protein Coding	7.44	DISEASES inferred ¹⁵
27	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.35	DISEASES inferred ¹⁵
28	MSH2	MutS Homolog 2	Protein Coding	7.31	DISEASES inferred ¹⁵
29	MIR652	MicroRNA 652	RNA Gene	7.29	DISEASES inferred ¹⁵ ¹⁵
30	MSH6	MutS Homolog 6	Protein Coding	7.28	DISEASES inferred ¹⁵
31	CDX2	Caudal Type Homeobox 2	Protein Coding	7.24	DISEASES inferred ¹⁵
32	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	7.21	DISEASES inferred ¹⁵
33	CCND1	Cyclin D1	Protein Coding	7.18	DISEASES inferred ¹⁵
34	ERCC6	ERCC Excision Repair 6, Chromatin Remodeling Factor	Protein Coding	7.15	DISEASES inferred ¹⁵ ¹⁵
35	SIL1	SIL1 Nucleotide Exchange Factor	Protein Coding	7.12	DISEASES inferred ¹⁵
36	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	7.08	DISEASES inferred ¹⁵
37	CDH1	Cadherin 1	Protein Coding	7.04	DISEASES inferred ¹⁵
38	MIR625	MicroRNA 625	RNA Gene	6.96	DISEASES inferred ¹⁵ ¹⁵
39	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.91	DISEASES inferred ¹⁵
40	SERPINA3	Serpin Family A Member 3	Protein Coding	6.86	DISEASES inferred ¹⁵ ¹⁵
41	KDM4C	Lysine Demethylase 4C	Protein Coding	6.85	DISEASES inferred ¹⁵ ¹⁵
42	HNF4A	Hepatocyte Nuclear Factor 4 Alpha	Protein Coding	6.8	DISEASES inferred ¹⁵
43	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.8	DISEASES inferred ¹⁵
44	SMAD4	SMAD Family Member 4	Protein Coding	6.8	DISEASES inferred ¹⁵
45	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	6.79	DISEASES inferred ¹⁵
46	AXIN1	Axin 1	Protein Coding	6.76	DISEASES inferred ¹⁵
47	IL6	Interleukin 6	Protein Coding	6.74	DISEASES inferred ¹⁵
48	AXIN2	Axin 2	Protein Coding	6.66	DISEASES inferred ¹⁵
49	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.65	DISEASES inferred ¹⁵
50	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.6	DISEASES inferred ¹⁵

Sources

Variations for Intestinal Benign Neoplasm

Sources

Expression for Intestinal Benign Neoplasm

Search GEO for disease gene expression data for Intestinal Benign Neoplasm.

Sources

Pathways for Intestinal Benign Neoplasm

Pathways related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁶	12.13	TP53 MIR20A MIR18A MIR17
2	Proteoglycans in cancer ³⁶	11.93	TP53 MIR21 KRAS HRAS
3	MicroRNAs in cancer ³⁶	11.93	TP53 MIR31 MIR21 MIR20A MIR192 MIR18A
4	DNA Damage Response (only ATM dependent) ¹	11.62	TP53 KRAS HRAS APC
5	Parkinsons Disease Pathway ¹	11.58	MIR20A MIR18A MIR17
6	Bladder cancer ³⁶ ¹	11.47	TP53 KRAS HRAS
7	Central carbon metabolism in cancer ³⁶	11.42	TP53 KRAS HRAS
8	Mitophagy - animal ³⁶	11.36	TP53 KRAS HRAS
9	Glioblastoma Multiforme ⁶³	11.3	TP53 KRAS HRAS APC
10	Extracellular vesicle-mediated signaling in recipient cells ¹	10.81	KRAS HRAS APC
11	p38MAPK events ⁶⁵	10.61	KRAS HRAS

Sources

GO Terms for Intestinal Benign Neoplasm

Cellular components related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.36	MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A

Biological processes related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell proliferation	GO:0008285	9.92	TP53 MIR21 MIR15A HRAS APC
2	positive regulation of angiogenesis	GO:0045766	9.73	MIR31 MIR21 MIR20A MIR143
3	negative regulation of gene expression	GO:0010629	9.73	TP53 MIR21 MIR20A MIR17 MIR124-1 HRAS
4	Ras protein signal transduction	GO:0007265	9.72	TP53 KRAS HRAS
5	negative regulation of inflammatory response	GO:0050728	9.71	MIR31 MIR20A MIR15A MIR124-1
6	positive regulation of vascular smooth muscle cell proliferation	GO:1904707	9.63	MIR21 MIR20A MIR17
7	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.56	MIR20A MIR17
8	positive regulation of metalloendopeptidase activity	GO:1904685	9.54	MIR21 MIR17
9	negative regulation of sprouting angiogenesis	GO:1903671	9.54	MIR20A MIR18A MIR17
10	positive regulation of vascular smooth muscle cell differentiation	GO:1905065	9.51	MIR21 MIR124-1
11	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.5	MIR21 MIR20A MIR143
12	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.49	MIR21 MIR17
13	response to isolation stress	GO:0035900	9.48	KRAS HRAS
14	miRNA mediated inhibition of translation	GO:0035278	9.43	MIR31 MIR21 MIR20A MIR17 MIR15A MIR124-1
15	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.33	MIR20A MIR17 MIR143
16	gene silencing by miRNA	GO:0035195	9.28	MIR31 MIR21 MIR20A MIR192 MIR18A MIR17

Molecular functions related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA binding involved in posttranscriptional gene silencing	GO:1903231	9.28	MIR31 MIR21 MIR20A MIR192 MIR18A MIR17

Sources

Sources for Intestinal Benign Neoplasm

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia